Diagnostic Testing for HER2, HER3, and TROP2 and Treatment Implications in Metastatic Breast Cancer

Download this slideset for expert perspectives on key nuances of HER2 testing in metastatic breast cancer and how test results inform HER2-targeted therapy decisions.
Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 10.1 MB
Released: July 30, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Daiichi Sankyo, Inc.

Related Content

Slides from Joyce O’Shaughnessy, MD, on measures of treatment benefit for HR+/HER2- early breast cancer from Clinical Care Options (CCO)

Joyce O'Shaughnessy, MD Released: June 15, 2021

Slides from Sara Hurvitz, MD, FACP, on neoadjuvant therapy with CDK4/6 inhibitors for HR+/HER2- early breast cancer from Clinical Care Options (CCO)

Sara Hurvitz, MD, FACP Released: June 15, 2021

MONALEESA-3 updated survival analysis with ribociclib + fulvestrant in advanced breast cancer, from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 11, 2021

GeparNUEVO survival outcomes with durvalumab + neoadjuvant chemo in early triple-negative breast cancer from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue